Sabrin Albeituni, PhD

Sabrin Albeituni, PhD

  • Department of Cancer Predisposition Postdoctoral Fellow

Departments

Divisions

Education

BS - Birzeit University, West Bank, the Palestinian Territories
MS - University of Louisville, Louisville, Kentucky
PhD - University of Louisville, Louisville, Kentucky

Honors & Awards

  • 2019 Milstein Travel Award-International Cytokine and Interferon Society
  • 2018 Milstein Travel Award-International Cytokine and Interferon Society
  • 2018 Stemcell Technologies’AAI 2018 Travel Award
  • 2018 American Association of Immunologists (AAI) Trainee Abstract Award
  • 2017 American Association of Immunologists (AAI) Trainee Abstract Award
  • 2015 American Association of Immunologists (AAI) Trainee Abstract Award
  • 2015 John Richard Binford Memorial Award
  • 2015 Graduate Dean’s Citation, Commencement Award- Fall 2015
  • 2014 Condict Moore Graduate Student Research Award -First Place - James Graham Brown Cancer Center Annual Research Retreat
  • 2013 Michael K. Tanner Award for Excellence in Graduate Student Sciences - University of Louisville
  • 2010-2012 Fulbright Scholarship

Research Interests

I am a postdoctoral research fellow with a strong interest in understanding the regulation of T cell responses by myeloid cells during normal immune homeostasis and in disorders associated with hyperinflammation. My main research focus in the Nichols’ laboratory is to investigate the cellular mechanisms governing the pathogenesis of a fatal hyperinflammaltory cytokine syndrome called hemophagocytic lymphohistiocytosis (HLH). In addition, I am interested in investigating the mechanisms of JAK1/2 inhibition in pre-clinical models as a potential salvage treatment for HLH.

Selected Publications

Albeituni S, Verbist KC, Tedrick PE, Tillman H, Picarsic J, Bassett R, Nichols KE. Mechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosis. Blood. 2019. 134(2):147-159. PMID: 31015190.

Crayne CB, Albeituni S, Nichols KE, Cron RQ. The Immunology of Macrophage Activation Syndrome. Front Immunol. 2019. 10:119. PMID: 30774631.

Weaver LK, Minichino D, Biswas C, Chu N, Lee JJ, Bittinger K, Albeituni S, Nichols KE, Behrens EM. Micriobiota-dependent signals are required to sustain TLR-mediated immune responses. JCI Insight. 2019. PMID: 30626747.

Verweyen E, Holzinger D, Weinhage T, Hinze C, Wittkowski H, Pickkers P, Albeituni S, Verbist K, Nichols KE, Schulert G, Grom A, Foell D, Kessel C. Synergistic TLR/IFNa/b-signaling facilitates escape of IL-18 exprsssion from endotoxin tolerance. American J Respir and Crit Care Med. 2019. In press.

Albeituni SH, Ding C, Liu M, Hu X, Luo F, Kloecker G, Bousamra M 2nd, Zhang HG, Yan J. Yeast-Derived Particulate b-Glucan Treatment Subverts the Suppression of Myeloid-Derived Suppressor Cells (MDSC) by Inducing Polymorphonuclear MDSC apoptosis and Monocytic MDSC Differentiation to APC in Cancer. J Immunol 196(5):2167-80, 2016. PMID:26810222.

Yaddanapudi K, Rendon B, Lamont G, Kim EJ, Al Rayyan N, Richie J, Albeituni S, Waigel S, Wise A, Mitchell R. MIF is necessary for late-stage melanoma patient MDSC immune suppression and differentiation. Cancer Immunol Res 4(2):101-12, 2016. PMID: 26603621.

Liu M, Luo F, Ding C, Albeituni S, Hu X, Ma Y, Cai Y, McNally L, Sanders MA, JainD, Kloecker G, Bousamra M 2nd, Zhang H, Higashi RM, Lane A, Fan TM, Yan J. Dectin-1 Activation by a Natural Product β-Glucan Converts Immunosuppressive Macrophages into an M1-like Phenotype with Tumoricidal Activity. J Immunol 195(10):5055-65, 2015. PMID:26453753.

Hudson SV, Huang JS, Yin W, Albeituni S, Rush J, Khanal A, Yan J, Ceresa BP, Frieboes HB, McNally LR. Targeted noninvasive imaging of EGFR-expressing orthotopic pancreatic cancer using multispectral optoacoustic tomography. Cancer Res 74:6271-9, 2014. PMID:25217521.

Albeituni SH, Yan J. The effects of beta-glucans on dendritic cells and implications for cancer therapy. Anti-cancer Agents Med Chem 13:689-98, 2013. PMID:23092290.

Albeituni SH, Ding C, Yan J. Hampering immune suppressors: therapeutic targeting of myeloid-derived suppressor cells in cancer. Cancer J 19:490-501, 2013. PMID:24270348.

Last update: November 2019